News | April 08, 2025
Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated
